Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Aon names interim CFO as Edmund Reese exits the firm
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c